<unk>  is a rule of thumb that a patient is at high risk of a fatal drug-induced liver injury (DILI) if given a medication that causes hepatocellular injury (not Hepatobiliary injury) with jaundice. The law is based on observations by<unk>  Zimmerman, a major scholar of drug-induced liver injury. Some have suggested the principle be called a<unk> pothesis or observation.<unk>  cases have three components: * The drug causes hepatocellular injury, generally defined as an elevated ALT or AST by 3-fold or greater above the upper limit of normal. Often with aminotransferases much greater (5-10x) the upper limit of normal. * Among subjects showing such aminotransferase elevations, they also have elevation of their serum total bilirubin of greater than 2× the upper limit of normal, without findings of cholestasis (defined as serum alkaline phosphatase activity less than 2× the upper limit of normal). * No other reason can be found to explain the combination of increased aminotransferase and serum total bilirubin, such as viral hepatitis, alcohol abuse, ischemia, preexisting liver disease, or another drug capable of causing the observed injury. In Zimmerman's analysis of 116 patients with hepatocellular injury and jaundice due to drug exposure, 76% went on to either require a liver transplant or died. Other studies have reported a lower but still significant mortality of 10%.
Hy's law
Lightwood's law
Farr's laws
McNeill's law
Ribot's law
Davis's law
Laura's Law
Sutton's law